Risk factors

The company faces going concern doubts and sufficient cash only into the third quarter of 2026. Management shifted its pipeline strategy toward acquiring or licensing new neurology and oncology drug candidates. Full-time employee headcount doubled from four to eight people alongside a complete executive leadership transition.

New risks focus on funding rademikibart, Simcere-related Renminbi transfers, regulatory conditions, reimbursement, and patient enrollment.

Canton Strategic Holdings pivoted from biotechnology to a digital asset treasury strategy holding Canton Coin (CC).

Clinical delays plague our Influenza A program following a failed Phase 2a trial and a major CRO dispute over $6,309,000. Going concern doubts intensify as accumulated losses reach $342.2 million and additional warrant issuances create shareholder dilution.

Cash dropped to $11.9 million by December 31, 2025, increasing the need for external financing. Regulatory approvals from the FDA and global data protection compliance introduce significant new legal and financial hurdles.

Cal Redwood Acquisition Corp. is a blank check company with until May 27, 2027 to consummate an initial business combination.

Net losses grew to $8.5 million in 2025 with an accumulated deficit reaching $49.3 million.

Clearthink 1 Acquisition Corp. is a blank check company formed for a business combination, with risks centered on sponsor control, redemption mechanics, and target evaluation.

Torrid highlights escalating international tariff pressures on its apparel supply chain, particularly regarding imports from China.

Accumulated deficit reached $39.0 million with cash insufficient for the next twelve months, threatening going concern status.

Customer concentration is more quantified: Raytheon, Sikorsky, Lockheed Martin and the Air Force represented 38%, 20%, 11% and 11% of 2025 revenue.

Cycurion expanded its risk disclosures heavily with new additions regarding government funding uncertainties, federal cost cuts, and speculative crypto investments.